Clinical activity of GITR-mediated ICS using TRX-518, a humanised agonistic GITR glycosylated IgG1 mAb, was evaluated in 43 patients with refractory solid tumours including 1 HCC, 1 fibrolamellar, and 1 CCA patient (30). Here, TNFRSF18 is linked to hepatocellular carcinoma.